Gloyn group

Martijn van de Bunt

Martijn van den Bunt

Novo Nordisk postdoctoral fellow

Address:

Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ

&

Wellcome Trust Centre for Human Genetics, Roosevelt Dr.
Oxford, OX3 7BN

Email

Research overview

I am currently a Novo Nordisk postdoctoral research fellow based at Oxford Centre for Diabetes Endocrinology & Metabolism and Wellcome Trust Centre for Human Genetics at the University of Oxford. After finishing my medical training in the Netherlands (University of Amsterdam), I moved to Oxford on a Nuffield Department of Medicine Prize Studentship to pursue a DPhil under the supervision of Anna Gloyn and Mark McCarthy.

My research aims improve our understanding of islet biology and pathophysiology through the integrative analysis of gene expression and transcriptional regulatory mechanisms in key type 2 diabetes tissues – primarily focussing on the human pancreatic islet. With my multi-disciplinary skill set, which combines clinical training, wet lab experience, and computational biology, I can generate and analyse these large islet datasets as well as tease out the biology locked within. My work in this area has recently been awarded an American Society for Human Genetics (ASHG) Charles J. Epstein Trainee Award for Excellence in Human Genetics Research.

Selected publications

Pasquali L, Gaulton KJ, Rodríguez-Seguí SA et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet 2014;46:136-43.

Tattikota SG, Rathjen T, McAnulty SJ et al. Argonaute2 Mediates Compensatory Expansion of the Pancreatic β Cell. Cell Metab 2014;19:122-134.

van de Bunt M, Gaulton KJ, Parts L, Moran I et al. The miRNA Profile of Human Pancreatic Islets and Beta-Cells and Relationship to Type 2 Diabetes Pathogenesis. PLoS One 2013;8:e55272.

Kailey B, van de Bunt M, Cheley S et al. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells. Am J Physiol Endocrinol Metab 2012;303:E1107-16.

Morán I, Akerman I, van de Bunt M et al. Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab 2012;16:435-48.

Pal A, Barber TM, van de Bunt M et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med 2012;367:1002-11.

Beer NL, Osbak KK, van de Bunt M et al. Insights into the pathogenicity of rare missense GCK variants from the identification and functional characterization of compound heterozygous and double mutations inherited in cis. Diabetes Care 2012;35:1482-4.

Parts L, Hedman ÅK, Keildson S et al. Extent, causes, and consequences of small RNA expression variation in human adipose tissue. PLoS Genet 2012;8:e1002704.

McCulloch LJ, van de Bunt M, Braun M et al. GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus. Mol Genet Metab 2011;104:648-53.

van de Bunt M, Gloyn AL. From genetic association to molecular mechanism. Curr Diab Rep 2010;10:452-66.